2011
DOI: 10.1271/bbb.110538
|View full text |Cite
|
Sign up to set email alerts
|

Antidiabetic Effects ofVigna nakashimaeExtract indb/dbMice

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
5
0

Year Published

2012
2012
2021
2021

Publication Types

Select...
8

Relationship

1
7

Authors

Journals

citations
Cited by 11 publications
(5 citation statements)
references
References 25 publications
(25 reference statements)
0
5
0
Order By: Relevance
“…Since the components that exert the antiobesity effect have not yet been characterized, further study is needed to characterize the antiobesity component of V. nakashimae extract. According to our previous 9) and current results, VN extract has diverse bioactivities that improve metabolic disturbances including type2 diabetes and obese and non-alcoholic fatty liver as compared with another phytochemicals.…”
Section: Discussionmentioning
confidence: 81%
See 1 more Smart Citation
“…Since the components that exert the antiobesity effect have not yet been characterized, further study is needed to characterize the antiobesity component of V. nakashimae extract. According to our previous 9) and current results, VN extract has diverse bioactivities that improve metabolic disturbances including type2 diabetes and obese and non-alcoholic fatty liver as compared with another phytochemicals.…”
Section: Discussionmentioning
confidence: 81%
“…Tel: +82-51-510-8468; Fax: +82-51-510-8437; E-mail: jung0603@pusan.ac.kr Abbreviations: ACC, acetyl-CoA carboxylase; aP2, adipocyte fatty acid binding protein; AMPK, AMP-activated protein kinase; C/EBPs, CCAAT/enhancer binding proteins; FAS, fatty acid synthase; HFD, high-fat diet; LPL, lipoprotein lipase; NAFLD, non-alcoholic fatty liver disease; PPAR, peroxisome proliferator-activated receptor KK-A(y) mice and a streptozotocin-induced type1 diabetes model. 7,8) Recently, we reported that V. nakashimae (VN), another species of Vigna widely cultivated in Korea, has antidiabetic effects in db/db mice via inhibition of -glucosidase activity, 9) but its antiobesity effect has not been explored.…”
Section: )mentioning
confidence: 99%
“…OGTT was performed on two days, with 6 mice on each test day divided into the following groups: (A) control (1.5 g glucose per kg bodyweight); (B) GLE (1.5 g glucose + 400 mg cGLE per kg bodyweight) and (C) GFE (1.5 g glucose + 400 mg GFE SFE per kg bodyweight). Extract doses were chosen based on several studies investigating the effect of phytogenic substances on post‐prandial glucose response . Test solutions were orally administered by gavage, and blood samples were collected from the tail tip before and 30, 60, 90, and 120 min after glucose load with subsequent blood glucose measurements using a glucometer Contour XT instrument (Bayer, Germany).…”
Section: Methodsmentioning
confidence: 99%
“…Thirty minutes after IBU administration, all mice group III-V were consecutively given glucose solution (Yusoff et al, 2015;Pattanayak et al, 2009;James et al, 2009;Gunawan-Puteri et al, 2018). Blood was collected from the lateral tail vein, and blood glucose was measured using GlucoDr®auto glucometer (All Medicus Co. Ltd) at 0 (before treatment), 15, 30, 60, 90 and 120 min after the sugar challenge (Wulandari, 2016;Yeo et al, 2011). The trapezoidal rule was used to determine the area under the curve (AUC) blood glucose (Wongnawa et al, 2014;Eyesin et al, 2010;Jo et al, 2011;Fransisca et al, 2018).…”
Section: Oral Glucose Tolerance Testmentioning
confidence: 99%